Advertisement
Advertisement
COLL
Collegium Pharmaceutical, Inc. Common Stock
24.21
USDSponsored
-0.95
-3.78%
Nov 06, 15:59 UTC -5
Closed
After-Market
24.20
-0.02
-0.06%
Collegium Pharmaceutical, Inc. Common Stock (COLL) Earnings
COLL Earnings Reports
Positive Surprise Ratio
COLL beat 22 of 44 last estimates.
50%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$229.34M
/$2.03
Implied change from Q3 26 (Revenue/ EPS)
+6.01%
/+3.57%
Implied change from Q4 25 (Revenue/ EPS)
+11.63%
/-0.49%
Collegium Pharmaceutical, Inc. Common Stock earnings per share and revenue
On Nov 05, 2026, COLL reported earnings of 1.96 USD per share (EPS) for Q3 26, beating the estimate of 1.89 USD, resulting in a 3.17% surprise. Revenue reached 216.34 million, compared to an expected 221.62 million, with a -2.38% difference. The market reacted with a +6.29% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 5 analysts forecast an EPS of 2.03 USD, with revenue projected to reach 229.34 million USD, implying an increase of 3.57% EPS, and increase of 6.01% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.02
Actual
$0.06
Surprise
+144.90%
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.32
Actual
$0.36
Surprise
+9.16%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.36
Surprise
-11.15%
Profound Medical Corp. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.18
Actual
-$0.21
Surprise
-11.41%
Akebia Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.03
Actual
-$0.04
Surprise
-6.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Guardian Pharmacy Services, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.30
Actual
$0.33
Surprise
+7.84%
FAQ
What were Collegium Pharmaceutical, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Collegium Pharmaceutical, Inc. Common Stock reported EPS of $1.96, beating estimates by 3.17%, and revenue of $216.34M, -2.38% below expectations.
How did the market react to Collegium Pharmaceutical, Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 6.29%, changed from $23.67 before the earnings release to $25.16 the day after.
When is Collegium Pharmaceutical, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Collegium Pharmaceutical, Inc. Common Stock's next earnings report?
Based on 5
analysts, Collegium Pharmaceutical, Inc. Common Stock is expected to report EPS of $2.03 and revenue of $229.34M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.